BRINGING HEALTH INSIGHT
TREAT THE
UNTREATABLE
Our pipeline of novel therapies, which is built on our RBP4 (Retinol Binding Protein 4) IP Portfolio, is focused on meeting the unmet needs of patients suffering from blindness, liver disease and diabetes.
Novel Therapy for
UNMET MEDICAL NEED
Our lead candidate Tinlarebant, developed from our RBP4 intellectual property portfolio, is a novel oral therapy which is intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to GA. We are currently completing a two-year Phase 2 study of Tinlarebant in adolescent STGD1 subjects, conducting a two-year global Phase 3 study of Tinlarebant in adolescent STGD1 subjects (DRAGON) and enrolling patients in a two-year global Phase 3 study of Tinlarebant in GA (PHOENIX). DRAGON study is a multi-center, randomized, double masked, placebo controlled study to evaluate the safety and efficacy of Tinlarebant in the treatment of adolescent STGD1 patients. PHOENIX study is a multi-center, randomized, double‑masked, placebo-controlled study to evaluate the safety and efficacy of Tinlarebant in GA subjects. Tinlarebant has obtained Orphan Drug Designation in the United States and Europe and has been granted a Rare Pediatric Disease (RPD) designation and Fast Track Designation in the US.
Tinlarebant
LBS-008
Bringing Hope to
INCURABLE BLINDNESS
Dry AMD / Stargardt Disease
PHASE 3
LBS
009
Blocking the Path to
METABOLIC DISEASE
Non-Fatty Liver Disease / Type 2 Diabetes
PRECLINICAL
Patient Registry
Select Your Preferred Language:
Tinlarebant (LBS-008) – Phase 3 trial for Geographic Atrophy (the “Phoenix” trial)
Recruitment Status : Recruiting
Tinlarebant (LBS-008) – Phase 3 trial for Stargardt Disease (the “Dragon” trial)
Recruitment Status : Active: not recruiting
This trial is to assess the efficacy and safety of Tinlarebant in adolescent subjects with childhood-onset Stargardt Disease.
Tinlarebant (LBS-008) – Phase 1b/2 trial for Stargardt Disease
Recruitment Status : Active, not recruiting
This Phase 1b trial is to identify the optimal dose of Tinlarebant in adolescent subjects with childhood-onset Stargardt Disease. The Phase 1b trial is extended to a two year Phase 2 trial in assessing the safety and efficacy of Tinlarebant in adolescent subjects with childhood-onset Stargardt Disease.